|
Boston Scientific Corporation (BSX) |
|
|
|
| |
Boston Scientific Income Statement Quarterly
BSX
|
Select the Financial Report: |
Period: |
Fiscal Year: |
|
|
|
|
INCOME STATEMENT
(Quarterly GAAP In millions $) |
(Dec 31 2021)
IV. Quarter |
(Sep 30 2021)
III. Quarter |
(Jun 30 2021)
II. Quarter |
(Mar 31 2021)
I. Quarter |
(Dec 31 2020)
IV. Quarter |
| Revenue From Contract With Customer Excluding Assessed Tax |
|
2,932.00 |
3,077.00 |
2,752.00 |
|
| Revenue From Contract With Customer Excluding Assessed Tax |
|
- |
- |
- |
|
| Total Revenue |
3,127.00 |
2,932.00 |
3,077.00 |
2,752.00 |
2,708.00 |
| Cost of Goods and Services Sold |
972.00 |
900.00 |
945.00 |
894.00 |
999.00 |
| Gross
Profit |
2,155.00 |
2,032.00 |
2,132.00 |
1,858.00 |
1,709.00 |
| Selling, Administration, Marketing |
1,153.00 |
1,066.00 |
1,121.00 |
1,019.00 |
1,027.00 |
| Gain (Loss) on Disposition of Business |
-30.00 |
-40.00 |
-2.00 |
-6.00 |
- |
| Depriciation & Amortization |
192.00 |
184.00 |
180.00 |
185.00 |
194.00 |
| Research and Development Expense (Excluding Acquired in Process Cost) |
320.00 |
310.00 |
298.00 |
276.00 |
286.00 |
| Restructuring, Accretion & impairment charges |
220.00 |
137.00 |
48.00 |
5.00 |
45.00 |
| Other operatinig exp. /-income |
- |
- |
- |
-1.00 |
74.00 |
| Litigation Settlement, Expense |
128.00 |
- |
298.00 |
4.00 |
18.00 |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability |
-19.00 |
-26.00 |
-85.00 |
-6.00 |
2.00 |
| Fees and Commission |
11.00 |
14.00 |
12.00 |
12.00 |
13.00 |
| Total operating costs including COS |
2,947.00 |
2,545.00 |
2,815.00 |
2,382.00 |
2,658.00 |
| Operating income/-loss
|
180.00 |
387.00 |
262.00 |
370.00 |
50.00 |
|
Other Deductions / - Income |
| Interest expense |
87.00 |
86.00 |
86.00 |
82.00 |
96.00 |
| Interest income |
- |
- |
- |
- |
- |
| Net interest expense/-income |
87.00 |
86.00 |
86.00 |
82.00 |
96.00 |
| Loss/ -Gain on Investment |
- |
- |
- |
- |
- |
| Income from affiliates |
- |
- |
- |
- |
- |
| Unrealized Loss/ -Income |
- |
- |
- |
- |
- |
| Financing Loss/ -Income |
- |
- |
- |
- |
- |
| Other loss/ -income |
-26.00 |
-182.00 |
27.00 |
-37.00 |
-353.00 |
| Total costs & expenses |
3,008.00 |
2,449.00 |
2,928.00 |
2,427.00 |
2,401.00 |
| Income /-loss before income taxes |
119.00 |
483.00 |
149.00 |
325.00 |
307.00 |
| Income taxes expenses/-benefit |
25.00 |
64.00 |
-37.00 |
-16.00 |
95.00 |
| Income after income taxes |
95.00 |
419.00 |
186.00 |
341.00 |
209.00 |
| Net income/-loss
of other equity |
1.00 |
- |
- |
- |
-3.00 |
| Income/-loss
from cont. Ops. |
95.00 |
419.00 |
186.00 |
341.00 |
209.00 |
| Accounting change |
- |
- |
- |
- |
- |
| Discontinued operations |
- |
- |
- |
- |
- |
| Extraordinary items |
- |
- |
- |
- |
- |
| Net Income/-loss |
95.00 |
419.00 |
186.00 |
341.00 |
209.00 |
| Noncontrolling interests |
- |
- |
- |
- |
- |
| Prefered dividends |
97.00 |
-14.00 |
-14.00 |
-14.00 |
52.00 |
| Other |
- |
- |
- |
- |
- |
| Income/-loss to shareholder |
81.00 |
405.00 |
172.00 |
327.00 |
196.00 |
| EBIT |
206.00 |
569.00 |
235.00 |
407.00 |
403.00 |
| EBITD |
496.00 |
841.00 |
498.00 |
675.00 |
1,526.00 |
| EBITDA |
496.00 |
841.00 |
498.00 |
675.00 |
1,526.00 |
| Per
Share (GAAP Quarterly, in $) |
(Dec 31 2021)
IV. Quarter |
(Sep 30 2021)
III. Quarter |
(Jun 30 2021)
II. Quarter |
(Mar 31 2021)
I. Quarter |
(Dec 31 2020)
IV. Quarter |
| Basic EPS (excl. extra
items) |
0.06 |
0.28 |
0.12 |
0.23 |
0.14 |
| Extraordinary items |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Basic Net EPS |
0.06 |
0.28 |
0.12 |
0.23 |
0.14 |
| Basic shares outstanding (Mill.
of Units) |
1,425.40 |
1,423.80 |
1,421.30 |
1,418.70 |
1,427.60 |
| EPS other shares |
- |
- |
- |
- |
- |
| Diluted Net EPS |
0.06 |
0.28 |
0.12 |
0.23 |
0.14 |
| Diluted average shares (Mill.
of Units) |
1,436.30 |
1,435.60 |
1,432.50 |
1,430.80 |
1,427.60 |
| Dividend per share |
0.009 |
0.01 |
0.01 |
0.01 |
0.01 |
|
|
